Learn more about the treatment
for CML and Ph+ ALL
ICLUSIG has been with you since 2013. With over a decade of combined experience and data, we’ve built
confidence that ICLUSIG may improve patients’ futures.1,2
DISCOVERY OF ICLUSIG
Play the video below to learn more about the key milestones of ICLUSIG and discover the
progress made since 2013 in treating patients with CML and Ph+ ALL.
Adverse events should be reported. Reporting forms and information can be found at
www.hpra.ie.
Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number
1800-456-748.
You are now leaving the Incyte Iclusig website. This link will take you to a site that is not
owned or maintained by Incyte. Incyte is not responsible for the information contained on
third-party sites
You are now leaving the site www.iclusig.ie.
This link will take you to a site https://www.incyte.com, owned by Incyte Corporation and managed
by the company.